SCHEMBL5008530

SCHEMBL5008530

Cn1nc(C(C)(C)C)cc1Nc1ccccc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.52
LMNA P02545 2/20 0.51
GRN P28799 2/20 0.49
SORT1 Q99523 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 3/20 0.47
MAPK13 O15264 1/20 0.47
MAPK12 P53778 1/20 0.47
MAPK11 Q15759 1/20 0.47
GFER P55789 1/20 0.46
CNR2 P34972 1/20 0.46
TAS2R14 Q9NYV8 1/20 0.45
CDC25B P30305 1/20 0.45
CLCN2 P51788 1/20 0.45
AKR1B10 O60218 1/20 0.44
AKR1B1 P15121 1/20 0.44
AKR1C4 P17516 1/20 0.44
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008332 0.86 MAPK14 (0.48) MAPK14LMNAGRNSORT1KDM4E
SCHEMBL5253749 0.82 GFER (0.61) LMNAMAPTGFERTAS2R14CLCN2
SCHEMBL5008343 0.82 MEN1 (0.50) MAPK14LMNAGRNSORT1KDM4E
SCHEMBL5008749 0.82 MAPK14 (0.47) MAPK14LMNAGRNSORT1KDM4E
SCHEMBL3974243 0.81 DHODH (0.50) MAPK14LMNAGRNSORT1KDM4E
SCHEMBL14600240 0.81 MAPK14 (0.62) MAPK14GRNSORT1MAPTMAPK13
SCHEMBL5007743 0.81 CLCN2 (0.51) MAPK14GRNSORT1MAPTMAPK13
SCHEMBL5010659 0.81 MAPK14 (0.64) MAPK14LMNAMAPTMAPK13MAPK12
SCHEMBL5005267 0.81 MAPK14 (0.53) MAPK14LMNAGRNSORT1MAPT
SCHEMBL5473230 0.80 GFER (0.47) MAPK14LMNAKDM4EMAPTMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 MAPK14 1938/4885LMNA 3247/4885GRN 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.